Abstract
Esketamine nasal spray acted rapidly to reduce depressive symptoms in a 4‐week study of patients with major depressive disorder and active suicidal ideation with intent. The results offer promise for emergency treatment of a condition for which there is currently no approved therapeutic. Study results were published online May 12, 2020, in the Journal of Clinical Psychiatry.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
